Active immunization using dendritic cells mixed with tumor cells inhibits the growth of lymphomas. by Park, Jin Ny et al.
INTRODUCTION
Dendritic cells (DCs) are antigen-presenting cells (APC)
with a key role in the immune system as initiators and stimu-
lators of naive T-cell responses against microbial pathogens
and tumors (1). Since the recognition of DCs in lymphoid
organs in 1973 (2), research on these cells has increased
because they might be useful for antitumor immunotherapy
(1, 3, 4). Furthermore, the central role of DCs in the initia-
tion of immune responses and new methods for the genera-
tion of large numbers of pure DCs by culturing progenitor
cells in the presence of granulocyte-macrophage colony-stimu-
lating factor (GM-CSF), tumor necrosis factor (TNF)- and
interleukin (IL)-4, creates possibilities for the development
of novel immunotherapeutic strategies against tumors and
other diseases (5-8).
DCs are present in small numbers in most tissues, includ-
ing skin, lung, liver, spleen, blood, lymphoid organs, and
bone marrow (9). Morphologically, they are large cells with
elongated stellate dendrites. These cells have been shown to
internalize and process exogenous or endogenous antigens
efficiently, and to present soluble antigens as peptides in
conjunction with MHC classes I and II (10, 11). In addition,
DCs have the unique ability to cause clustering of naive T-
cells. They also respond to antigen by rapid upregulation of
the expression of MHC factors and co-stimulatory molecules,
the production of cytokines, and migration toward lym-
phatic organs (12, 13). DCs, helper T-cell-dependent anti-
body responses, as well as the generation of primary and
secondary cytotoxic T-cell responses to tumor-associated
antigens, have proven to be effective immunogens when
pulsed with tumor-associated antigens (9, 14). However, T-
cell defined epitopes that can be presented by DCs have not
been identified for most tumors. One study suggested that
immunization with undefined tumor antigens might be more
effective in eliciting antitumor immunity (15). Although
the use of a single antigen-derived epitope has been shown
to effect antitumor immunity in murine models, the presen-
tation of multiple antigen-derived epitopes may enhance
antitumor immunity. Johnston et al. demonstrated that the
increased immunogenicity of tumor cells expressing the B7.1
gene was caused by the expansion of the antigenic repertoire
of the tumor (16). Because of the extensive diversity of MHC
antigens, designing common peptides for T-cell recognition
for different individuals with the same disease may be diffi-
cult to prove (17). To circumvent this problem and to pro-
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Dendritic cells (DCs) are potent antigen-presenting cells for the induction and
activation of cytotoxic T lymphocytes. We tested whether bone marrow-derived
DCs are capable of inducing protective immunity against a murine lymphoma
(A20). DCs were grown from tumor-bearing BALB/c mice by culturing bone mar-
row cells. BALB/c mice were injected (sc) with A20 cells on day 0. Intraperitoneal
immunization with DCs mixed with lethally irradiated A20 cells were started
when the tumor reached ca. 4-5 mm in diameter (Group A) or on day -7 (Group
B). Booster immunizations were given every 3-4 days for four weeks. By 31 days in
group A, there was a significant reduction in tumor growth in the mice immunized
with DCs mixed with irradiated A20 cells as compared with the control groups (p
=0.016). In group B, tumor growth was completely inhibited and there was no
tumor growth following extended observations after completion of immunization.
Thus, DCs mixed with irradiated tumor cells can induce an antitumor effect. This
provides a rationale for the use of DCs mixed with irradiated tumor cells in
immunotherapy for minimal residual disease of lymphomas. 
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methods have been developed to isolate immunogenic pep-
tides from tumor cells. However, there is no defined stan-
dard method. Despite the advances in chemotherapy, includ-
ing high-dose therapy with autologous stem cell transplan-
tation for lymphomas, relapse of the underlying disease
remains a significant obstacle (18). Recent advances in can-
cer vaccine development now make it possible to consider
combining active specific immunotherapy as a strategy for
the elimination of minimal residual disease. 
The aim of this study was to assess the ability of bone
marrow-derived DCs to induce therapeutic and protective
immunity against a murine lymphoma model. Using immu-
nization with DCs mixed with lethally irradiated target
tumor cells, we investigated whether tumor cells, as a source
of undefined tumor antigens, could intensify the antitumor
immune response of DCs, and evaluated whether the sup-
pression of tumor growth was correlated with T-cell function.
MATERIALS AND METHODS
Mice
Female BALB/c AnN (BALB/c) mice (6-8 weeks old)
were purchased from Jackson Laboratories (Bar Harbor, ME,
U.S.A.) and housed in specific pathogen-free units of the
Animal Resources Center at Asan Institute for Life Science.
Mice were maintained and treated according to National
Institutes of Health guidelines. All aspects of the studies
requiring animal experimentation were approved by the
Asan Institute of Life Science Animal Care and Use Com-
mittee.
Cell Lines
A20 lymphoma cells were purchased from American Type
Culture Collection (ATCC: Rockville, MD, U.S.A.). This is
a BALB/c B lymphoma cell line derived from a spontaneous
reticulum cell neoplasm found in an old BALB/c mouse
(19, 20). Cells were maintained in complete RPMI 1640
medium (GIBCO BRL, Aithersburg, MD, U.S.A.) supple-
mented with 100 IU/mL penicillin (Sigma, St Louis, MO,
U.S.A.), 0.1 mg/mL streptomycin (Sigma), 10
-5 M -mer-
captoethanol (Sigma), and 10% fetal bovine serum (FBS:
GIBCO BRL). 
Tumor-Bearing Bone Marrow Cell Culture and Isola-
tion of Dendritic Cells
A20 tumor cells (2 10
6) were injected subcutaneously
(sc) into the shaved back of BALB/c mice. Animals were
sacrificed three weeks after the injection, when the tumor
reached 5-10 mm in diameter. Bone marrow cells were
obtained from the femurs and tibias of BALB/c mice as des-
cribed (5). After three washes in RPMI 1640, mononuclear
cells were obtained and allowed to adhere to a tissue culture
flask for 3 hr at 37 . The adherent cells were then removed
and non-adherent cells were placed in 100 mm diameter
tissue culture dishes at a concentration of 1 10
5/mL in the
medium supplemented with 20 ng/mL murine recombinant
(r) GM-CSF (R & D Systems, Minneapolis, MN, U.S.A.),
10 ng/mL murine IL-4 (R & D) and 2.5 ng/mL murine
TNF- (R & D). Culture dishes were fed once every three
days. On day 11, non-adherent cells were harvested and used
for assays and immunization.
Evaluation of Cell Yield and FACS Analysis
Cultured cells were washed once and an aliquot volume
was mixed 1:1 in Trypan blue solution (Sigma). Trypan blue
negative, and large cells were counted as viable under the
microscope in a Neubauer chamber and cells were identified
by their distinctive morphology. Cells (1 10
6) were incu-
bated with the corresponding antibody for 30 min at 4 .
The cells were then washed and fixed in 1% paraformalde-
hyde. Flow cytometric analysis was performed using a FAC-
Scan (Becton Dickinson, Mountain View, CA, U.S.A.). DCs
were phenotyped with antibodies to the following markers:
isotype controls for hamster IgG; rat IgG2a; DC markers
DEC-205 (NLDC-145) and CD11C; co-stimulatory/adhe-
sion molecules CD80 (B7-1) and CD86 (B7-2); macrophage
markers CD14 and F4/80, and granulocyte marker Gr-1
(Pharmingen, Hamburg, Germany).
Preparation of Splenocytes
Spleen cells were obtained from the same mice, and sus-
pended and red cells were lysed with ammonium chloride.
To obtain purified T-cells, spleen cells were incubated in tissue
culture flasks for 1 hr in medium as above, and non-adherent
cells were collected and filtered through a nylon wool column.
Mixed Leukocyte Reaction (MLR)
DCs (5 10
3) from BALB/c AnN mice were irradiated
(1,500 rads) to stimulate the proliferation of DCs and were
added to T-cells (5 10
4) from BALB/c mice. A20 cells (5
10
4 lethally irradiated at 10,000 rad) were co-cultured in
96-well plates for each immunized group. The cells were
co-cultured for three days at 37 (under 5% CO2). Cells
were divided into three groups: DCs mixed with T-cells,
lethally irradiated A20 cells plus T-cells, and T-cells only.
Each group of cells was incubated for 18 hr with 1  ci of
[
3H] thymidine (Amersham, Arlington Heights, IL, U.S.A.)
at the end of the three-day culture, and isotope incorporation
was determined using a liquid scintillation counter. Results
were tested three times in triplicates. 
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Cytotoxic activity of the stimulated cells was measured
using a 6 hr 
51Cr release cytotoxic assay (21). For the immu-
nization group, DCs (4 10
5) from BALB/c mice were irra-
diated (1,500 rads), added to T-cells (4 10
5) from BALB/c
mice, and 4 10
5 of lethally irradiated (10,000 rads) A20
cells, and co-cultured in 12-well plates for six days at 37
(under 5 % CO2). Control groups were cultured DCs mixed
with T-cells, T-cells mixed with lethally irradiated A20
cells, or T-cells alone. Target cells (A20 cells) were labeled
for two hours with 
51Cr at the end of the three day culture,
then washed three times and 2 10
4 of the target cells were
mixed with each group of effector cells. After incubation of
six hours, supernatants were harvested, and the amount of
51Cr release was measured using a Packard Parias gamma
spectrometer (Packard Instruments, Meridian, CT, U.S.A.).
Results were tested three times in triplicate. The maximum
and spontaneous release and the percentage of specific
release were determined as described (21).
Post-Tumor Induction Immunization 
For the evaluation of the effect of immunization on the
growth of the established tumor, mice were injected (sc) with
2 10
6 A20 cells. Intraperitoneal immunizations with 2 4
10
5 DCs mixed with lethally irradiated (10,000 rads) 2
10
6 A20 cells were started when the tumors reached 5-10 mm
in diameter.
Mice in control groups were given intraperitoneal inocu-
lations of phosphate-buffered saline solution (PBS), or 2-4
10
5 DCs alone. Each group contained five mice and booster
immunizations were performed once every three days for
four weeks.
Mice were examined daily, and tumor volumes were record-
ed daily with calipers.
Immunization Before Tumor Implantation
Intraperitoneal immunizations with 2-4 10
5 DCs mixed
with 2 10
6 lethally irradiated (10,000 rads) A20 cells were
started on day -7. The mice in control groups were given
intraperitoneal injections of PBS only. Booster immuniza-
tions were performed once every three days for four weeks.
On day 0, the mice were injected sc with 5 10
4 of A20
cells, and tumor volumes were recorded daily using calipers.
Evaluation of the Effect of Immunization on T-Cells
Splenocytes were obtained from each group of mice after
the final post-tumor induction immunization. Viable T-cells
were counted using trypan blue vital stain, and FACScan
analysis was performed to compare the ratio of CD4+/CD8+
cells using anti-CD4/FITC, anti-clone MT310+/ anti-CD8/PE,
and anti-clone DK 205 antibodies (DAKO, Denmark). Esti-
mation of the induction activity of T-cells after DC immuni-
zation was performed on 1 10
5 T-cells in a [
3H] thymidine
uptake test.
For the evaluation of the efficacy of immunization associ-
ated with alteration of the Th1/Th2 profile of the T-cells in
tumor-bearing mice, 1 10
6 of splenic T-cells were cultured
for three days at 37 (5% CO2) and the concentrations of
IL-2 and IL-4 proteins in supernatants were measured with
ELISA kits (R&D).
Apoptosis Assay
For the evaluation of the effect of immunization on tumor
tissue, tumor tissues were obtained from each group of mice
after the final post-tumor induction immunization. 
Demonstration of apoptosis in the tumors was performed
by the TdT-mediated biotinylated-dUTP nick end labeling
(TUNEL) method using the ApopTaq in situ apoptosis detec-
tion kit (Oncor, MD, U.S.A.) with slight modifications. Nuclei
of tumor sections were stripped from proteins by incubation
with 20  g/mL proteinase K for 15 min at room tempera-
ture. The sections were then washed in distilled water and
immersed in 3% H2O2 in methanol for 5 min to quench the
endogenous peroxidase activity. The tumor sections were
immersed in the kit’s equilibration buffer for 10 min. Ter-
minal deoxynucleotidyl transferase (TdT) and dUTP-digoxi-
genin were added to the sections, and the slices were incu-
bated in a humidified chamber at 37 for 1 hr. After wash-
ing in PBS, the sections were incubated with an anti-digoxi-
genin-peroxidase solution for 30 min. The slices were stained
with DAB/H2O2 solution (0.05% diaminobenzidine tetra-
chloride and 0.02% H2O2 in 50 mM Tris-HCl buffer), and
then counterstained with hematoxylin and eosin (22).
Statistical Methods
Different experimental groups within the study were com-
pared using the non-parametric Kruskal-Wallis, Friedman,
or Mann-Whitney tests. A p value <0.05 was considered
significant and statistical analysis was done using the SAS
program.
RESULTS
Development of BM-DCs
Clusters of round granulocytes developed around the third
day, and increasing numbers of macrophages adhered to the
plastic bottom of the well. By the fourth to the sixth day,
isolated aggregates of matured DCs were visible. Around the
seventh to the ninth day, DCs were enlarged and numerous
typical long and small dendritic processes were visible.
374 J. Park, C. Suh, J. Yang, et al.On day 11, the purity of DCs was >90% with a viability
of >90%. Fig. 1 shows a representative flow cytometer result
of the cellular phenotype of cultured DCs harvested on that
day. Repeated flow cytometry showed cultured cells to be
strongly positive for DEC-205 (88%) and CD11 (40.7%),
as well as the co-stimulatory molecules CD80 (98%) and
CD86 (97%). Only 7% of the cultured cells expressed F4/80,
the macrophage-specific marker, and only 2.3% expressed
Gr-1, the granulocyte-specific marker.
Mixed Leukocyte Reaction
To test whether the DCs generated from bone marrow of
tumor-bearing mice stimulate syngeneic T-cells, a [
3H] thymi-
dine incorporation test was performed. Bone marrow-derived
DCs mixed with lethally irradiated A20 tumor cells signifi-
cantly stimulated syngeneic T-cells, as compared with con-
trol groups (Fig. 2). Microscopic examination revealed that
DCs mixed with lethally irradiated A20 tumor cells stimu-
lated and induced cluster formation and aggregation of T-
cells.
Cytotoxic T Lymphocyte (CTL) Assay
Estimation of the induction and functional activity of
cytotoxic T lymphocytes after DC immunization was per-
formed by a 6 hr 
51Cr release cytotoxic assay. DCs were cul-
tured with T-cells at a ratio of 1:10 for five days and the
effector: target ratios were 20:1 in triplicate. DCs generated
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Fig. 2. Dendritic cell (DCs) generation from bone marrow (BM) of
tumor-bearing mice mixed with lethally irradiated tumor cells
stimulate syngeneic T-cells. BM-derived DCs (5 10
3) mixed
with 5 10
4 lethally irradiated (10,000 rads) A20 cells showed a
significantly increased stimulation of syngeneic T-cells (5 10
4:
p=0.015). 
* irradiated A20 cells.
Fig. 1. Fluorescence-activated cell sorting
(FACS) surface profile of bone marrow
dendritic cells (BM-DCs) from BALB/c
mice analysis at day 11. Mature BM-DCs
express more co-stimulatory molecules
(CD80, CD86), and DC markers (CD11c,
DEC-205), but less or no monocyte/macro-
phage markers (CD14, F4/80) or granu-
locyte marker (anti Gr-1). Isotype control
staining for hamster IgG and rat IgG2a
were used to set the marker lines (straight
lines).
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lethally irradiated tumor cells stimulated the CTL as mea-
sured by this assay (Fig. 3).
Effect of Immunization on the Growth of Established
Tumors-Immunization After Tumor Induction
To study the effects of immunization on the growth of
established tumors, intraperitoneal immunizations with DCs
mixed with lethally irradiated tumor cells were started when
the tumors reached ca. 5-10 mm in diameter, and continued
once every three days for four weeks. A significant reduction
in the primary tumor growth of A20 lymphomas was noted
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Fig. 3. Dendritic cell (DC) generation from bone marrow (BM) of
tumor-bearing mice mixed with lethally irradiated tumor cells sti-
mulate CTL. BM-derived DCs (4 10
4) mixed with 4 10
5 lethally
irradiated (10,000 rads) A20 cells showed increased stimulation
of CTL (4 10
5). 
* irradiated A20 cells.
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Fig. 4. The effect of immunization with dendritic cells (DCs) on the
growth of established tumors. BALB/c mice were injected (sc)
with 2 10
6 A20 lymphoma cells. Intraperitoneal immunization
with 2-4 10
5 DCs mixed with 2 10
6 lethally irradiated A20 cells,
2-4 10
5 DCs only or with phosphate-buffered saline solution
(PBS) alone, were started when the tumors reached 5-10 mm in
diameter. Each group contained five mice. Mean tumor sizes in
each group are given. p values for differences between the groups
of mice immunized with different methods are shown above the
data points.
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Fig. 5. The effect of immunization with dendritic cells (DCs) before
tumor implantation on subsequent tumor growth. Intraperitoneal
immunization of BALB/c mice with 2-4 10
5 DCs mixed with
lethally irradiated (10,000 rads) 2 10
6 A20 cells or phosphate-
buffered saline solution (PBS) were started before tumor induc-
tion on day 7. Mice were injected (sc) with 5 10
4 A20 lymphoma
cells on day 0. Immunization before tumor injection prevents tumor
growth.
day
A. 2-4 10
6 DC 18/47 17951 1935 1536/1150
+ 2 10
6 A20 cells
B. 2-4 10
6 DC 16/35 26324 2301 2229/1144
C. PBS 9/27 4045 796 130/81
Normal control 13/31 128 53 116/70
BALB/c mice were injected (sc) with 2 106 A20 lymphoma cells. Intra-
peritoneal immunization with 2-4 105 dendritic cells (DCs) mixed with
2 106 lethally irradiated (10,000 rads) A20 cells, 2-4 105 DCs only,
or phosphate-buffered saline solution (PBS) alone, were started when
the tumors reached c. 5-10 mm in diameter. For evaluation of the effect
of immunization on T-cells, [3H] thymidine uptake test, FACS scan analy-
sis of T-cells and IL-2/IL-4 assays (using ELISA) with T-cells from spleno-
cytes of each group were used.
CD4/CD8 
3[H] thymidine  IL2/IL4
(%)  uptake test (cpm) (pg/mL)
Immunization group
Table 1. The effect of immunization with dendritic cells on T-
cellsat day 31, and there were significant differences in the rates
of growth of lymphomas between groups (Fig. 4).
Effect of Immunization on the Growth of Established
Tumors-Immunization Before Tumor Induction
To test whether immunization with DCs mixed with
lethally irradiated tumor cells was capable of inducing protec-
tive antitumor immunity, immunization was started before
tumor induction. As shown in Fig. 5, immunization before
tumor injection could completely prevent tumor growth
and there was no growth after the completion of immuniza-
tion. By contrast, the mice of control groups showed progres-
sive tumor growth.
Effect of Immunization on T-Cells
Spleens were obtained from each group of mice after the
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Fig. 6. Microscopic findings of A20 lymphomas treated with PBS (A, B), DC (C, D), and DC mixed with irradiated A20 cells (E, F). Some
of the apoptotic cells showed fragmentation of the condensed nucleus into multiple apoptotic bodies. (A, C, E: Hematoxylin and eosin
staining  400). Apoptotic cells are identified by dark brown nuclear staining using the TUNEL method. (B, D, F:  200).
A B
C D
E Ffinal post-tumor induction immunization. As summarized
in Table 1, the ratio of CD4+ to CD8+ cells was highest in
the group immunized with DCs mixed with lethally irradi-
ated tumor cells. The mice of both immunized groups and
the tumor-bearing control group had higher [
3H] thymidine
uptakes than normal controls. Mice of the immunized groups
showed considerably higher levels of IL-2 and IL-4 than mice
of the non-immunized group.
Evaluation of Apoptosis by In Situ End-Labeling
Tumor tissues were obtained from each group of mice
after the final post-tumor induction immunization. Micro-
scopically, A20 lymphomas treated with PBS (A, B), DC
(C, D) and DC mixed with irradiated A20 cells (E, F), showed
some apoptosis with fragmentation of the condensed nucle-
us in multiple apoptotic bodies (Fig. 6A, C, E), and the apop-
totic cells were identified by dark brown nuclear staining using
the TUNEL method (Fig. 6B, D, F). The apoptosis indices
were 0.5%, 4%, and 6% for B, D and E, respectively.
DISCUSSION
In this study, we used bone marrow-derived DCs to induce
a therapeutic and protective immune response against a murine
lymphoma. DCs mixed with lethally irradiated lymphoma
cells as a source of tumor antigens stimulated an effective
anti-lymphoma immune response. This was associated with
an increase in tumor-specific cytotoxic-T cell responses.
Although the exact mechanism of antitumor immunity was
not defined, it is possible that the lethal irradiation of the
A20 lymphoma cells resulted in rapid cell death with the
release of cellular antigens that were then processed by the
adjacent DCs (23), which then initiated the stimulation of
tumor-specific cytotoxic T-cells. 
Bone marrow-derived myeloid lineage DCs provide criti-
cal antigen-presenting cell activity for initiating specific T
lymphocyte activation and proliferation; thus many studies
have used bone marrow-derived DC for immunotherapy
(24-26). Several studies applied a combination of cytokines
including GM-CSF, TNF- and IL-4 to harvest a large num-
ber of purified DCs from bone marrow cells (6-8). We also
obtained DCs with morphologically typical dendrites using
GM-CSF, TNF- and IL-4. In this study, we reduced the
dose of GM-CSF and increased that of TNF- at a later stage
of ex vivo culture. This resulted in minimal contamination
with granulocytes and macrophages, and we obtained func-
tionally active mature DCs. Our FACS analysis using the
DC markers CD11c and DEC-205, and the co-stimulatory
molecules CD80 and CD86 showed higher level of DCs at
day 11 of culture. However, the macrophage-specific mark-
ers F4/80 and CD14, and granulocyte-specific marker Gr-1
were expressed at much lower levels. We also found that
DCs mixed with lethally irradiated A20 tumor cells stimu-
lated T-cells and induced cluster formation and aggregation
of T-cells. 
We performed [
3H] thymidine incorporation assays to
show that DCs generated from the bone marrow of the tumor-
bearing mice significantly stimulated syngeneic T-cells as
compared with control groups. The cytotoxic activity of the
T lymphocytes measured by 
51Cr release was stimulated in
the mice immunized with the DCs mixed with lethally
irradiated tumor cells. If we were to increase the ratio of the
effector cells, this might stimulate the CTL significantly.
Immunization before tumor implantation resulted in com-
plete prevention of tumor growth, and there was no tumor
growth after completion of the immunization. We observed
that these mice were alive without any tumor growth for
more than 12 weeks. This result suggests the feasibility of
active tumor-specific immunotherapy with autologous den-
dritic cell transplantation as a strategy for the elimination of
minimal residual disease (MRD) of lymphomas. Our results
with syngeneic bone marrow-derived DCs for immunother-
apy suggest that effective ex vivo expansion and maturation
of DC from autologous stem cells could be an important and
useful tool for immunotherapy.
In many model systems, the balance between the cytokines
induced from Th1 and Th2 effector cells plays an important
role in the regulation of immune responses. A Th1-positive
cell response is thought involved in cellular and tumor immu-
nity, and Th2-positive cells are associated with the suppres-
sion of cytolytic activity (27, 28). In this study, we tried to
evaluate the possible role of Th1/Th2 cell balance in the
immune response to DCs sensitized with irradiated tumor
cells. Tumor progression in control mice was associated with
a decreased absolute level of Th1-cell induced cytokine (IL-
2) and Th2-cell induced cytokine (IL-4), whereas effective
immunization blocks tumor progression, which in turn was
closely associated with increased absolute levels of Th1-cells
(IL-2). However, we found no significant differences in
Th1/Th2 cell ratios between the groups. The induction of
antitumor immunity by bone marrow-derived DCs requires
the presentation of MHC class-II restricted molecules and
activation of CD4+ T-cells (29). Our study demonstrated
that the cultured DCs mixed with whole but dead tumor
cells as a vaccine and induced antitumor immunity and com-
plete prevention of tumor growth in the co-adjuvant treat-
ment group. Recently, Kim et al. demonstrated that NK
cells were required during the priming of cytotoxic T-cell
response by DCs-based tumor vaccine and DCs can induce
an antitumor immune response by enhancing NK cell-de-
pendent CTL activation (30). 
Evaluation of apoptosis by TUNEL demonstrated that
the PBS-alone treated control group showed an apoptotic
index of 0.5% (Fig. 6B), while in the DC-only treated group
it was 4% (Fig. 6D), and in the group treated with DC
mixed with irradiated A20 cells treated group it was 6%
378 J. Park, C. Suh, J. Yang, et al.(Fig. 6F). Programmed cell death was thus increased over
tenfold in the treated group F.
We conclude that DCs mixed with irradiated tumor cells
as a source of undefined tumor antigens can induce an effective
antitumor immune response and completely prevent tumor
growth. It also provides a rationale for the use of DCs mixed
with irradiated tumor cells as an immunotherapy for MRD
of lymphomas. Further studies on better methods of cultur-
ing DCs, optimizing the means of antigen loading on DCs
and the most efficacious vaccination schedules and dosages
should be investigated. Moreover, the mechanism by which
DC vaccine can provide the desired immunity remains to
be determined.
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